Fusion Pharmaceuticals (FUSN) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

Fusion Pharmaceuticals Revenue Highlights


Latest Revenue (Y)

$2.07M

0

Fusion Pharmaceuticals Revenue by Period


Fusion Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$2.07M41.55%
2022-12-31$1.46M1.46%
2021-12-31$1.44M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--

Fusion Pharmaceuticals generated $2.07M in revenue during NA 2023, up 41.55% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Fusion Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-03-31--100.00%
2023-12-31$33.64M1576.77%
2023-09-30$2.01M5800.00%
2023-06-30$34.00K21.43%
2023-03-31$28.00K-80.00%
2022-12-31$140.00K-15.66%
2022-09-30$166.00K-70.88%
2022-06-30$570.00K-2.56%
2022-03-31$585.00K-1.52%
2021-12-31$594.00K82.77%
2021-09-30$325.00K-37.62%
2021-06-30$521.00K100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--

Fusion Pharmaceuticals generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Fusion Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
HRMYHarmony Biosciences$582.02M$186.04M
CHRSCoherus BioSciences$257.24M$64.98M
SPROSpero Therapeutics$96.73M$10.20M
BCYCBicycle Therapeutics$26.98M$2.68M
FENCFennec Pharmaceuticals$21.64M$25.26M
NAMSNewAmsterdam Pharma Company$14.09M$1.40M
IKNAIkena Oncology$9.16M-
JANXJanux Therapeutics$8.08M$1.25M
BOLTBolt Biotherapeutics$7.88M$1.27M
FUSNFusion Pharmaceuticals$2.07M-
KROSKeros Therapeutics$151.00K$83.00K
RAPTRAPT Therapeutics--
GRCLGracell Bio--
BCABBioAtla--
OLMAOlema Pharmaceuticals--
PASGPassage Bio--
NLTXNeurogene--
PMVPPMV Pharmaceuticals--
EWTXEdgewise Therapeutics--
RLMDRelmada Therapeutics--

FUSN Revenue FAQ


Fusion Pharmaceuticals's yearly revenue for 2023 was $2.07M, representing an increase of 41.55% compared to 2022. The company's yearly revenue for 2022 was $1.46M, representing an increase of 1.46% compared to 2021. FUSN's yearly revenue for 2021 was $1.44M, representing an increase of 100.00% compared to 2020.

Fusion Pharmaceuticals's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $33.64M, a 1576.77% increase from the previous quarter (Q3 2023), and a 23925.71% increase year-over-year (Q4 2022). FUSN's quarterly revenue for Q3 2023 was $2.01M, a 5800.00% increase from the previous quarter (Q2 2023), and a 1108.43% increase year-over-year (Q3 2022).

Fusion Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 43.61%, and for the last 5 years (2019-2023) was 0%.